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J.D. Armitage,1* N.J. Lindsey2 and S. Homer-Vanniasinkam11The Vascular Surgical Unit, The General Infirmary at Leeds, Leeds, and 2The Department of Biomedical
Sciences, The University of Bradford, Bradford, UKObjectives. It is hypothesised that endothelial cell reactive antibodies (ECRA) play a role in the progression of PAD through
activation of endothelial cells and the release of inflammatory cytokines. We aimed to test this hypothesis by assessing levels
of ECRA, E-selectin and IL-6 in patients with PAD of varying severity in a case controlled study.
Design, materials, methods. Patients were assessed clinically and with ankle–brachial pressure indices. Patients with
critical ischaemia (CI, nZ30), stable claudicants (SC, nZ30), and age-matched controls (AMC, nZ20) were studied.
Antibody, E-selectin and IL-6 levels were measured using ELISA.
Results. ECRA levels were significantly raised in the CI group over AMC.
IL-6 levels were significantly elevated in both SC and CI over the control group and in CI over SC.
There were no significant differences in E-selectin levels between the AMC, SC and CI.
Conclusion. Our findings support the hypothesis that autoantibodies play a role in promoting PAD by elevating IL-6. The
absence of an elevation in E-selectin in this study may be due to its short half-life, and casts doubt on its value as a marker of
inflammation in atherosclerosis.Keywords: Peripheral arterial disease; Endothelial cell reactive antibodies; Anticardiolipin; Anti-b2-glycoprotein I;
Interlukin-6.Introduction
Peripheral arterial disease (PAD) is a common and
disabling condition, which affects 4.6% of the popu-
lation aged between 55 and 74.1 Meta-analysis of
studies on the outcome of patients with PAD reveals,
that over a 5-year period, as little as five percent of
patients deteriorate to a degree that necessitates
surgery and only two percent require an amputation.2
Furthermore, of those patients requiring amputation,
less than half had symptoms of intermittent claudica-
tion 6 months previously,3 suggesting that a small
cohort of individuals have an accelerated form of the
disease. Several traditional risk factors are recognised
to promote the development of PAD, however, these
do not fully explain the relatively benign progressionhe Annual Meeting of the Surgical Academic Research
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in the few.4
The formation of atheroma in the arterial wall is
increasingly recognised as an inflammatory process.5
Greater understanding of this process, which includes
the accumulation of macrophages and T lymphocytes,
suggests that an autoimmune response directed
against the vascular endothelium may play a role in
the initiation and progression of atherogenesis.5
Endothelial cell reactive antibodies (ECRA) are a
heterogeneous group of autoantibodies directed
against antigens in the membrane of endothelial cells
(EC). Originally described in 1971,6 these antibodies
have been demonstrated in patients, with a number of
autoimmune diseases, in whom accelerated athero-
sclerosis is well recognised.7,8
Anticardiolipin (anti-CL) antibodies and, their
major subpopulation, anti-b2-glycoprotein I (anti-
b2GPI) antibodies are two ECRA which have been
identified in these patients. Animal and in vitro studies
have demonstrated a potential pathogenic role for
these antibodies by the up-regulation of adhesion
molecule expression and cytokine and chemokineEur J Vasc Endovasc Surg 31, 170–175 (2006)
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prothrombotic state.9,10 Anti-CL antibodies have been
shown in several studies to be correlated with angina,
myocardial infarction and cardiac death.11,12 Anti-
b2GPI antibodies have been found to be abundant in
atherosclerotic plaques and elevated levels have been
associated with unstable angina and ischaemic
stroke.13–15 However, the significance of these anti-
bodies in peripheral arterial disease has not been
elucidated to date.
This study aims to investigate whether levels of
anti-CL and anti-b2GPI antibodies are elevated in
patients with peripheral arterial disease and whether
they are a marker of increased disease severity. In
addition the levels of interleukin-6 and E-selectin, two
markers of endothelial activation will be examined.
This will enable the testing of the hypothesis that
elevated autoantibody levels may be implicated in the
development and progression of PAD.Materials and MethodsPatients
This study was approved by the Ethical Committee
of the Leeds Teaching Hospital University Trust
and written consent was obtained from all those
that took part. All patients attending the Vascular
Unit were considered for entry into the study.
Patients were selected on the basis of a history of
claudication16 or critical ischemia17 and their ankle
brachial pressure index. Two groups were studied:
stable claudicants (SC) had symptoms of inter-
mittent claudication with no subjective alteration in
their exercise tolerance over the prior 6 months,
plus an ankle brachial pressure index of less than
0.9 (diabetic toe pressure !70 mmHg); critical
ischaemia (CI) these patients had persistent
ischemic rest pain requiring analgesia for O2
weeks or ulceration/gangrene of the foot or toes,
plus an ankle systolic pressure of less than
50 mmHg (diabetic toe pressure !40 mmHg).
Patients were excluded if they had suffered a
myocardial infarction or stroke in the past 3
months as this might have altered their antibody
profile, if they had presented with a proven
thrombotic event or if they had ever been given a
diagnosis of autoimmune disease, vasculitis or
malignancy. In addition a control group was
recruited: age matched controls (AMC), this
group had no symptoms or clinical signs of
vascular disease and had an ankle brachialpressure index of greater than 0.9. Thirty subjects
were recruited into each of the study groups, and
20 patients into the control group. This was done
over a period of 3 months.Clinical assessment
A full medical history was taken from each subject
entered into the trial, including a detailed history of
cardiac, cerebral and peripheral vascular symptoms,
risk factors and previous events. Current medication
was recorded, as well as a detailed smoking history.
An ECG and serial blood pressure measurements were
taken. An uncuffed 50 ml venous blood sample was
collected and sent for analysis of full blood count,
APTT, glucose, lipids, U&E and LFT’s. The remaining
blood was collected in serum tubes (Vacuettew Greiner
International, Austria), centrifuged at 3000 rpm for
15 min, aliquoted into 0.5 ml units and stored at
K80 8C until required.Elisa assay
Antibodies to anticardiolipin and anti-b2-gycopro-
tein I were measured using a commercially
available enzyme-linked immunosorbent assay
(ELISA), (Bindazyme MK040/MK041, UK). Inter-
leukin-6 was measured using a commercially
available ELISA (R&D Systems D6050, USA). E
selectin levels were assessed using an in-house
ELISA. In brief, microtitre plates (Costar, Corning
Life Sciences, The Netherlands) were coated over-
night at 4 8C with a monoclonal antibody against
human E-selectin (BBA16, R&D Systems, USA) at a
concentration of 2 mg/ml. After washing with 0.1 M
PBS/0.05% Tween-20, the plates were blocked with
2% BSA for 1 h at room temperature (RT).
Subsequently patient serum samples (1:1000
dilution in PBS) were added in triplicate. Recombi-
nant E-selectin (ADP1, R&D Systems, USA) was
used as calibration with eights standards on each
plate (range 1 mg/ml–7.8 ng/ml). The results from
these eight calibration standards plus a zero
standard were used to plot a calibration curve.
Wells were washed and biotinylated polyclonal
antibody against human E-selectin (BAF575, R&D
Systems, USA) was added at a concentration of
0.2 mg/ml for 1 h at RT. E-selectin was detected by
the addition of streptavidin-peroxidase (1 mg/ml)
(S-2438, Sigma-Aldrich, UK) diluted of 1:200 for 1 h
at RT. Finally the plates were washed and the
colour reaction was initiated by the addition of
substrate (tetramethylbenzidine and H2O2). AfterEur J Vasc Endovasc Surg Vol 31, 2 2006
Table 1. Patients and control characteristics
AMC SC CI
n 20 30 30
Mean age 67 66 69
Range 56–78 52–80 35–84
Sex M/F 9/11 13/17 17/13
Smoking 10 (50)*1 17 (57) 17 (57)
Mean ABPI 1.0 0.71 0.31
Amputation 0 0 8 (27)
Isch ulcer 0 0 12 (40)
PMHx
Art surgery 0 2 (7)*2 13 (43)*2
MI 0 10 (34)*3 16 (53)*3
CVA/TIA 0 1 (3)*4 12 (40)*4
Hypertension 0 21 (70) 19 (63)
Diabetes 0 6 (20)*5 11 (37)*5
Anticoag
Aspirin 0 23 (77) 12 (40)
Clopidogrel 0 0 8 (27)
Warfarin 0 0 10 (33)
None 100% 7 (23) 0
Statin 0 12 (40) 13 (43)
Values are number of patients (%). Corresponding *(No) indicates
significance p!0.05 between the two variables. There was no
significant difference in the ages or smoking habits of the AMC, SC
and CI groups. There was a significant increase in the incidence of
diabetes, myocardial infarction, arterial surgery and CVA/TIA in CI
when compared with SC. No significant difference in the incidence
of hypertension, antiplatelet or statin use was observed between the
SC and CI groups.
Fig. 1. The percentage of subjects in each group with
pathogenic levels of anti-cardiolipin or anti-b2-glycoprotein
I antibodies. Seven patients had pathological levels of anti-
b2GPI antibodies, 6 CI and 1 SC (anti-b2GPI O22 U/ml).
Seven patients had pathological levels of anti-CL antibodies,
6 CI and 1 SC (anti-CL O11 GPL/ml). Three of the patients
with critical ischaemia had pathological levels of both anti-
CL and anti-b2GPI antibodies.
J. D. Armitage et al.17220 min the colour reaction was stopped by adding
200 ml per well of 3 M H2SO4. The plates were read
at 490 nm. The results were calculated from the
standard curve. The accuracy of this ELISA was
validated by using a range of positive and negative
standards on each plate and also by performing the
assay in duplicate.Statistical analysis
Antibody levels for each group are presented as
medianGinter-quartile range. The differences
between antibody levels for each group were assessed
using an ANOVA with post hoc analysis. Differences
in group characteristics were assessed using the
independent samples t-test.Table 2. Anti-cardiolipin antibody, anti-b2-glycoprotein I antibody, E
AMC
Anticardiolipin (U/ml) 1.97*1 (1.67–2.42)
Anti-b2-Glycoprotein I (U/ml) 16.07*3 (15.09–17.68)
E-selectin ng/ml 9.47 (9.00–12.03)
Interlukin-6 (pg/ml) 6.03*5,6 (5.39–6.83)
Values are expressed as median (interquartile range). Corresponding *(N
CL and anti-b2GPI antibody levels were significantly raised in the CI gro
0.0121; anti-b2GPI: CI 18.72 u/ml vs AMC 16.07 u/ml, pZ0.0013. Anti-C
vs SC 16.35 u/ml, pZ0.0374. There were no significant differences in E
significantly elevated in both SC and CI over the control group. IL-6: A
24.88 pg/ml, p!0.00016. There was also a significant increase between
Eur J Vasc Endovasc Surg Vol 31, 2 2006Results
The groups were well matched for sex and age (Table 1).
Levels of cigarette smoking were similar in all groups.
Mean ABPI was in keeping with the selection criteria, as
is the past medical history of each group. As would be
expected cardio/cerebro-vascular events were more
common in patients with critical ischaemia (CI)
although only cerebrovascular events reached statistical
significance. This fact is reflected in the level of
antiplatelet agent use. It is interesting to note that less
than half of the patients with PAD were taking a statin at
the time of recruitment (2001). With new guidelines,
lowering the threshold for statin use in patients with
vascular disease it is likely that statin use will be much
higher in this population now.
The stable claudicants showed some elevation of
both anti-CL levels and anti-b2GPI although this did
not reach significance. The patients with critical
ischaemia had significantly elevated mean levels of
both anti-CL and anti-b2GPI antibodies when-selectin and interlukin-6 levels for each of the four groups
SC CI
2.51*2 (1.96–3.43) 2.93*1,2 (2.27–5.45)
16.35*4 (14.07–18.58) 18.64*3,4 (16.33–22.00)
9.92 (9.53–12.75) 9.92 (5.90–13.55)
8.36*5,7 (7.20–10.02) 22.35*6,7 (12.88–67.82)
o) indicates significance p!0.05 between the two variables. Both anti-
up over SC and AMC. Anti-CL: CI 2.77 u/ml vs AMC 1.97 u/ml, pZ
L: CI 2.77 u/ml vs SC 2.51 u/ml, pZ0.0342; anti-b2GPI: CI 18.72 u/ml
-selectin levels between the AMC, SC and CI IL-6 levels were
MC 6.03 pg/ml vs SC 8.36 pg/ml, p!0.00015; AMC 6.03 pg/ml vs CI
SC and CI. IL-6: SC 8.36 pg/ml vs CI 24.88 pg/ml, p!0.0217.
Fig. 2. The concentration of anti-cardiolipin antibody in each
group. Anti-CL antibody levels were significantly elevated
in the CI group compared with both SC and AMC. Graph
indicates median value for each group. Bars indicate
interquartile range. Matched symbols indicate a significant
difference between groups, p!0.05.
Fig. 4. The concentration of interlukin-6 in each group. IL-6
levels were significantly elevated in the CI group compared
with both SC and AMC. There was a significant increase in
IL-6 levels between SC and AMC. Graph indicates median
value for each group. Bars indicate interquartile range.
Matched symbols indicate a significant difference between
groups, p!0.05.
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and 3. Seven patients had pathological levels of anti-
b2GPI antibodies, 6 CI and 1 SC (anti-b2GPI O22 U/
ml). Seven patients had pathological levels of anti-CL
antibodies, 6 CI and 1 SC (anti-CL O11 GPL/ml).
Three of the patients with critical ischaemia had
pathological levels of both anti-CL and anti-b2GPI
antibodies (Fig. 1). There was a significant elevation of
IL-6 in patients with stable claudication when
compared with the control group and a much larger
elevation in IL-6 was seen in patients with critical
ischaemia compared with controls (Fig. 4). The level of
IL-6 seen in patients with critical ischaemia was
significantly raised compared with patients with
stable claudication.Fig. 3. The concentration of anti-b2-glycoprotein I in each
group. Anti-b2GPI antibody levels were significantly elev-
ated in the CI group compared with both SC and AMC.
Graph indicates median value for each group. Bars indicate
interquartile range. Matched symbols indicate a significant
difference between groups, p!0.05.There was no significant elevation in E-selectin
levels in the patients with PAD compared with
controls. Stable claudicants and patients with critical
ischaemia had similar levels of E-selectin (Table 2).
Each group was independently examined for
differences in antibody level, IL-6 and E-selectin level
related to sex, smoking, diabetes, MI, CVA, hyperten-
sion, previous arterial surgery and previous amputa-
tion. No significant differences were found. In
addition, as the groups were well matched for sex,
age and smoking, these factors were examined using
the data as a whole, independent of group to see if they
significantly altered antibody, IL-6 and E-selectin
levels. No significant difference was found.Discussion
This study set out to examine the levels of antic-
ardiolipin and anti-b2-glycoprotein antibodies in
patients with PAD and assess their potential patho-
genicity in its development and progression. The
groups of patients were chosen to represent cohorts
with varying severities of atherosclerosis. The patients
with critical ischaemia represent a cohort with more
severe disease, which may have resulted from an
accelerated atherosclerosis.3 However, there was no
significant difference in risk factors such as smoking,
hypertension, and diabetes between the two groups.
The observation that traditional risk factors do not
accurately predict the progression to critical ischaemia
is support by epidemiological data.4 The prior
identification of this cohort would be of great value
in clinical practice, allowing aggressive therapy forEur J Vasc Endovasc Surg Vol 31, 2 2006
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studies reported here show that the mean levels of
both anti-CL and anti-b2GPI antibody levels were
significantly elevated in the patients with critical
ischaemia when compared with the stable claudicants
and age-matched controls. Furthermore nine of the
critically ischaemic patients showed pathological
levels of antibodies compared with two stable
claudicants and no controls. In addition we have
shown that patients with stable claudication and
critical ischaemia have progressively higher levels of
interleukin-6. This would support our hypothesis that
these autoantibodies are elevated in a proportion of
patients with more severe PAD and that they may play
a role in the accelerated progression of PAD seen in
some patients.
Anti-phospholipid antibodies, such as anti-CL
antibodies, were initially identified in patients who
suffered from increased venous and arterial thrombo-
sis. It has been shown that b2-glycoprotein I is a key
co-factor for the recognition of cardiolipin.18 The
antibodies have been found in patients with auto-
immune diseases, such as SLE and the anti-phospho-
lipid syndrome, and have been linked to increased
cardiovascular disease in these patients.19 Whilst these
antibodies can increase the likelihood of thrombosis,
patients with either SLE or APS also show an
accelerated atherosclerosis, raising the possibility
that these antibodies play a role in the pathogenesis
of atherosclerotic disease.7,8 High levels of anti-CL
have been shown to be an independent risk factor for
myocardial infarction and cardiac death in middle
aged men.12,11 Anti-b2GPI antibodies have been
shown to be elevated in patients with ischaemic
heart disease compared with controls. In addition,
whilst 45% of patients with unstable angina had
elevated levels of anti-b2GPI antibody, only 11.8% of
patients with stable, effort induced angina showed
elevated levels of the antibody, suggesting a role in the
progression of the disease.13 Several studies have
shown an association between elevated levels of anti-
b2GPI antibodies and ischaemic stroke.14,15,20 Whilst
this clinical evidence demonstrates an association
between raised anti-CL and anti-b2GPI antibody
levels and atherosclerosis, it cannot determine
whether these antibodies play a role in the pathogen-
esis of atherogenesis.
The pathogenesis of atherosclerosis is a complex
process. No single factor can be identified as playing a
pivotal role in its development or progression; rather it
relies on a complex jigsaw of diverse processes. Anti-
CL and anti-b2GP1 are just two of a large hetero-
geneous group of antibodies, which react with the
vascular endothelium. These endothelial cell reactiveEur J Vasc Endovasc Surg Vol 31, 2 2006antibodies (ECRA) were first described in 1971.6 Anti-
phospholipid,21 anti-DNA,22 ANCA23 and anti-tubu-
lin24 antibodies have all been identified as endothelial
cell reactive antibodies that can up-regulate proin-
flammatory markers in endothelial cells. The hetero-
geneity of endothelial autoantigens suggests that
reactivity with cardiolipin or b2GPI may only identify
a sub-group of autoantibodies that can accelerate
atherosclerosis.
Anti-CL and anti-b2GPI antibodies have been
shown to induce an endothelial pro-atherogenic
phenotype mediated by the expression of the adhesion
molecules E-selectin, ICAM-1 and VCAM-1 and
increased secretion of inflammatory cytokines IL-1b
and IL-6 in in vitro studies.25–29 These studies show
that patients with stable claudication had elevated IL-6
levels when compared with controls and that patients
with critical ischaemia had significantly higher levels
of IL-6 still. This supports the in vitro work and lends
weight to our hypothesis that these autoantibodies are
contributing to the accelerated progression of disease
seen in the small cohort of patients who go on to
develop critical ischaemia. The absence of an increase
in E-selectin levels was surprising given the strong
in vitro evidence that anti-CL and anti-b2GPI anti-
bodies cause up regulation of E-selectin.25,28,29 How-
ever, the short term and relatively transient expression
of E-selectin may mean that it is not the most suitable
marker of chronic inflammation in these patients. In
conclusion this study has shown for the first time that
significantly elevated levels of anti-CL and anti-b2GPI
antibodies are present in PAD patients with the most
advanced disease, implicating these antibodies in the
progression of PAD. The lack of a direct correlation
between patients with elevated anti-CL and anti-
b2GPI antibodies and IL-6 demonstrates that further
work needs to be done to examine the full panel of
ECRA, each of which in vitro, have been shown to
cause pro-inflammatory effects on EC and, therefore,
have the potential to be pro-atherogenic.References
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